1. 6th largest Pharma by revenue.
2. Multiple Sclerosis sales doubles to over $1 billion. Aubegio is the fastest growing oral MS drug in the U.S. Lemtrade sales in the US increased by 614%.
3. Group sales excluding diabetes is up by 4.7%
4. Double digit growth in rare diseases driven by new patient accrual
5. 7.3% increase in vaccine sales driven by Emerging Markets.
6. Group sales grew by 10% in 2015 from currency tailwinds.
7. It is the 4th largest in prescription sales (2014 figure)
8. 3rd largest vaccine revenue in 2014
9. An international presence in 100+ countries and solid growth in EM led by Asia.
10. 43 molecules and vaccines in the R&D portfolio including 14 in late stage
11. Up to 18 R&D launches expected by 2020
12. 30% of Sanofi revenue and its highest sales region is Emerging Markets, which is the fastest growing segment.
13. Strong free cash flow and relatively low debt
14. 3 launches of major products – Toujeo, Praluent, and Dengvaxia
15. Significant R&D alliances in Oncology and Diabetes
16. 2020 strategic roadmap to create long term value
17. First ever Dengue Vaccine introduced
18. Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
1. R&D expense of 14.7% of sales is below that of its direct competitors
2. Profit margin of 16.2% puts Sanofi at the middle of its competitors (3rd lowest from 6)
3. Negative revenues from two products which have impacted EPS: Afrezza and Auvi Q
4. Loss of Patent for Lantus in 2014, highest selling diabetes medication product.
5. Expected vaccine revenue forecast in 2020 unchanged from 2014 position
6. Went from 4th to 6th position in global revenue sales from 2014 to 2015
7. Diabetes sales have declined by 7%
8. Established products sales have declined by 2.3%
9. Substantial share of revenue continues to come from a few flagship products
10. Global diabetes sales to decline by 408% by 2018 (Lantus, 17% of...